Advanced Filter

Filter by Group

Filter by Market Availability

Displaying all 2 drugs
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Synonyms: … Cilgavimab
Matched Name: … Cilgavimab
Matched Description: … Cilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on ... [A243351, A243356, L39411] As the RBD binding site of cilgavimab does not overlap with that of [tixagevimab ... [A243351, A243361, L39411] Cilgavimab is not approved for any indication by the FDA. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Synonyms: … Tixagevimab
Matched Name: … Tixagevimab
Matched Description: … Tixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on ... [A243351, A243356, L39411] As the RBD binding site of tixagevimab does not overlap with that of [cilgavimab ... [A243351, A243361, L39411] Tixagevimab is not approved for any indication by the FDA. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Displaying all 2 drugs